Login
Search
Search
0 Dates
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
QUALITY OF LIFE OF HEART FAILURE PATIENTS IN PORTUGAL: A CROSS-SECTIONAL STUDY (PRiMe STUDY)
Session:
Painel 2 - Insuficiência Cardíaca 8
Speaker:
Marta Afonso-Silva
Congress:
CPC 2020
Topic:
D. Heart Failure
Theme:
10. Chronic Heart Failure
Subtheme:
10.7 Chronic Heart Failure - Other
Session Type:
Posters
FP Number:
---
Authors:
Marta Afonso-Silva; Maria Cary; José Pedro Guerreiro; Mariana Romão; António Teixeira Rodrigues ; Pedro A. Laires
Abstract
<p><strong>Background: </strong>Heart failure (HF) is a major worldwide health problem with direct impact on patients’ daily activities, accounting for a significant social and economic burden. The aim of this study was to characterize the quality of life (QoL) of HF patients recruited in a Portuguese observational study (PRiMe).</p> <p><strong>Methods:</strong> The PRiMe study is a cross-sectional and multicenter study. Adult patients (≥18 years) or caregivers with a prescription of sacubitril/valsartan were recruited through Portuguese community pharmacies. All community pharmacies associated with the Portuguese National Association of Pharmacies were invited to participate. Data was collected through a structured questionnaire applied to patients or caregivers by the pharmacist. Generic and specific QoL was measured through the EQ-5D-3L and the Minnesota Living with Heart Failure Questionnaire (MLHFQ), respectively, which were only applied to patients. Higher values of MLHFQ and lower values of EQ-5D index score address worse health status. This study was approved by the competent Ethics Committee and is compliant with the General Data Protection Regulation.</p> <p><strong>Results:</strong> A total of 285 patients were recruited (23% through their caregiver). The median age of patients was 72 years (IQR, 63-80), and the majority were male (66%). These were multicomorbid patients with hypertension (69%), atrial fibrillation (55%), hypercholesterolemia (53%), sleep disorders (47%), anxiety (40%), diabetes (40%), acute myocardial infarction (35%), among others. HF had been diagnosed for a median of 5 years (IQR, 2-11) and according to the self-assessed NYHA, the majority of patients (66%) were NYHA II or III. The mean EQ-5D index score (SD) of this population was 0.6 (0.3) and the mean VAS utility value (SD) was 61 (20). The mean total score (SD) of the specific QoL instrument was 37 (24). Both EQ-5D index score and total MLHFQ score worsened with the increase of the self-assessed NYHA: EQ-5D ranged from 0.9 to 0.5 and MLHFQ from 14 to 49 for self-assessed NYHA class I and IV, respectively.</p> <p><strong>Conclusions:</strong> Our findings show that HF patients in Portugal have their QoL impacted by the disease and that worse functional status patients suffer a higher impact. The adoption of measures that directly improve patients’ QoL should be a priority in HF management.</p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site